T-DXd Wins Breakthrough Status From FDA
FDA Grants BTD to T-DXd in HER2+ BC With Residual Invasive Disease Post NAT
| Read More |
Pimicotinib Earns Approval in China for Tenosynovial Giant Cell Tumors
| Read More |
Videos
|
MATTERHORN Trial Design and DFLOT Adoption: Integrating Immunotherapy Into Perioperative Practice
|
Introducing COPERNICUS: Clinical Gaps and the Rationale for a New First Line Strategy
|
Trending
|
Distress Screening: Making the Fifth Vital Sign Integral to Oncology Care
|
|
PRO Data Support T-DXd Combo in HER2+ Advanced Breast Cancer
|